Similar articles

Abstract: ObjectiveWhether vortioxetine has a utility as an adjuvant drug in the treatment of bipolar depression remains controversial. This study aimed to validate the efficacy and safety of vortioxetine in bipolar depression.
MethodsPatients with bipolar II depression were enrolled in this prospective, two-center, randomized, 12-week pilot trial. The main indicator for assessing treatment effectiveness was a Montgomery-Asberg Depression Rating Scale (MADRS) of ≥50%. All eligible patients initially received four weeks of lurasidone monotherapy. Patients who responded well continued to receive this kind of monotherapy. However, no-response patients were randomly assigned to either valproate or vortioxetine treatment for eight weeks. By comprehensively comparing the results of MADRS over a period of 4‍‒‍12 weeks, a systematic analysis was conducted to determine whether vortioxetine could be used as an adjuvant drug for treating bipolar depression.
ResultsThirty-seven patients responded to lurasidone monotherapy, and 60 patients were randomly assigned to the valproate or vortioxetine group for eight weeks. After two weeks of combined valproate or vortioxetine treatment, the MADRS score in the vortioxetine group was significantly lower than that in the valproate group. There was no difference in the MADRS scores between the two groups at 8 and 12 weeks. The incidence of side effects did not significantly differ between the valproate and vortioxetine groups. Importantly, three patients in the vortioxetine group appeared to switch to mania or hypomania.
ConclusionsThis study suggested that lurasidone combination with vortioxetine might have potential benefits to bipolar II depression in the early stage, while disease progression should be monitored closely for the risk of switching to mania.

沃替西汀辅助治疗双相抑郁发作的临床疗效和安全性

[1]AliZ, TeginC, El-MallakhRS, 2020. Evaluating lurasidone as a treatment option for bipolar disorder. Expert Opin Pharmacother, 21(3):253-260.

[2]BaldwinDS, ChronesL, FloreaI, et al., 2016. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol, 30(3):242-252.

[3]Bang-AndersenB, RuhlandT, JørgensenM, et al., 2011. Discovery of 1-‍[2-‍(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem, 54(9):3206-3221.

[4]BerhanA, BarkerA, 2014. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry, 14:276.

[5]CalabreseJR, PikalovA, StreicherC, et al., 2017. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol, 27(9):865-876.

[6]CalabreseJR, DurgamS, SatlinA, et al., 2021. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry, 178(12):1098-1106.

[7]CheniauxE, NardiAE, 2019. Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder. Expert Opin Drug Saf, 18(10):893-913.

[8]CiprianiA, FurukawaTA, SalantiG, et al., 2018. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, 391(10128):1357-1366.

[9]ClementeAS, DinizBS, NicolatoR, et al., 2015. Bipolar disorder prevalence: a systematic review and meta-analysis of the literature. Braz J Psychiatry, 37(2):155-161.

[10]CrumpC, SundquistK, WinklebyMA, et al., 2013. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry, 70(9):931-939.

[11]D'AndreaG, de RonchiD, GiaccottoL, et al., 2019. Vortioxetine treatment-emergent mania in the elderly: a case report. Australas Psychiatry, 27(4):413.

[12]de Diego-AdelinoJ, CrespoJM, MoraF, et al., 2022. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opin Drug Saf, 21(5):673-690.

[13]DelBelloMP, GoldmanR, PhillipsD, et al., 2017. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry, 56(12):1015-1025.

[14]Dell'OssoB, AriciC, CafaroR, et al., 2021. Antidepressants in bipolar disorder: analysis of correlates overall, and in BD-I and BD-II subsamples. J Affect Disord, 292:352-358.

[15]DomeP, RihmerZ, GondaX, 2019. Suicide risk in bipolar disorder: a brief review. Medicina (Kaunas), 55(8):403.

[16]ForteA, BaldessariniRJ, TondoL, et al., 2015. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Affect Disord, 178:71-78.

[17]FountoulakisKN, KelsoeJR, AkiskalH, 2012. Receptor targets for antidepressant therapy in bipolar disorder: an overview. J Affect Disord, 138(3):222-238.

[18]FountoulakisKN, TohenM, ZarateCA, 2024. Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data. Eur Neuropsychopharmacol, 81:1-9.

[19]GoldbergJF, PerlisRH, BowdenCL, et al., 2009. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry, 166(2):173-181.

[20]GrandeI, BerkM, BirmaherB, et al., 2016. Bipolar disorder. Lancet, 387(10027):1561-1572.

[21]GreenbergWM, CitromeL, 2017. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet, 56(5):493-503.

[22]IshibashiT, HorisawaT, TokudaK, et al., 2010. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT₇) and 5-HT_1A receptor activity. J Pharmacol Exp Ther, 334(1):171-181.

[23]KaltenboeckA, WinklerD, KasperS, 2016. Bipolar and related disorders in DSM-5 and ICD-10. CNS Spectr, 21(4):318-323.

[24]KatoT, IshigookaJ, MiyajimaM, et al., 2020. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry Clin Neurosci, 74(12):635-644.

[25]KetterTA, SarmaK, SilvaR, et al., 2016. Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study. Depress Anxiety, 33(5):424-434.

[26]LeverichGS, AltshulerLL, FryeMA, et al., 2006. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry, 163(2):232-239.

[27]LiZJ, LiuSH, WuQX, et al., 2023. Effectiveness and safety of vortioxetine for the treatment of major depressive disorder in the real world: a systematic review and meta-analysis. Int J Neuropsychopharmacol, 26(6):373-384.

[28]LiuBS, ZhangY, FangH, et al., 2017. Efficacy and safety of long-term antidepressant treatment for bipolar disorders—a meta-analysis of randomized controlled trials. J Affect Disord, 223:41-48.

[29]LoebelA, CucchiaroJ, SilvaR, et al., 2014a. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry, 171(2):160-168.

[30]LoebelA, CucchiaroJ, SilvaR, et al., 2014b. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry, 171(2):169-177.

[31]McGirrA, VöhringerPA, GhaemiSN, et al., 2016. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry, 3(12):1138-1146.

[32]McIntyreRS, CalabreseJR, 2019. Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Curr Med Res Opin, 35(11):1993-2005.

[33]McIntyreRS, ChaDS, KimRD, et al., 2013. A review of FDA-approved treatment options in bipolar depression. CNS Spectr, 18(Suppl 1):4-20.

[34]McIntyreRS, SuppesT, EarleyW, et al., 2020. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. CNS Spectr, 25(4):502-510.

[35]MeltzerHY, CucchiaroJ, SilvaR, et al., 2011. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry, 168(9):957-967.

[36]MitchellPB, GoodwinGM, JohnsonGF, et al., 2008. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord, 10(1Pt 2):144-152.

[37]MontgomerySA, AsbergM, 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry, 134(4):382-389.

[38]MørkA, PehrsonA, BrennumLT, et al., 2012. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther, 340(3):666-675.

[39]PacchiarottiI, VerdoliniN, 2021. Antidepressants in bipolar II depression: yes and no. Eur Neuropsychopharmacol, 47:48-50.

[40]PaeCU, WangSM, HanCS, et al., 2015. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci, 40(3):174-186.

[41]PostRM, 2016. Treatment of bipolar depression: evolving recommendations. Psychiatr Clin North Am, 39(1):11-33.

[42]RobertsRJ, LohanoKK, El-MallakhRS, 2016. Antipsychotics as antidepressants. Asia Pac Psychiatry, 8(3):179-188.

[43]SheehanDV, LecrubierY, SheehanKH, et al., 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry, 59(Suppl 20):22-33.

[44]SidorMM, MacqueenGM, 2011. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry, 72(2):156-167.

[45]SiwekM, ChrobakAA, SoltysZ, et al., 2022. A naturalistic, 24-week, open-label, add-on study of vortioxetine in bipolar depression. Psychiatr Pol, 56(3):509-522.

[46]SobreiraG, OliveiraJ, BrissosS, 2017. Vortioxetine-induced manic mood switch in patient with previously unknown bipolar disorder. Braz J Psychiatry, 39(1):86.

[47]SuttajitS, SrisurapanontM, ManeetonN, et al., 2014. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther, 8:827-838.

[48]TakaesuY, TakeshimaM, WatanabeK, 2022. Effectiveness and tolerability of lurasidone for bipolar types I and II and other specified bipolar depression: a 12-week observational study. J Clin Psychopharmacol, 42(5):485-488.

[49]TeraoT, 2021. Neglected but not negligible aspects of antidepressants and their availability in bipolar depression. Brain Behav, 11(8):e2308.

[50]TondoL, BaldessariniRJ, VázquezG, et al., 2013. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders. Acta Psychiatr Scand, 127(5):355-364.

[51]WongDF, KuwabaraH, BrašićJR, et al., 2013. Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology (Berl), 229(2):245-252.

[52]YalinN, YoungAH, 2020. Pharmacological treatment of bipolar depression: what are the current and emerging options?Neuropsychiatr Dis Treat, 16:1459-1472.

[53]YathamLN, KennedySH, ParikhSV, et al., 2018. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord, 20(2):97-170.

[54]YoshikawaA, LiJ, MeltzerHY, 2020. A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs. Pharmacogenomics J, 20(2):260-270.

[55]YoungRC, BiggsJT, ZieglerVE, et al., 1978. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry, 133:429-435.